iclusig
Incyte acquires Ariad’s European operations in $140 million deal
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ariad, Incyte, Operations, buy out, european, iclusig, leukaemia, out-license
Incyte (NASDAQ: INCY) has entered into an agreement with Ariad Pharmaceuticals (NASDAQ: ARIA) that will see the company acquire Ariad’s …
EMA keeps Ariad cancer drug on the market
October 13, 2014Sales and Marketing Ariad, CML, EMA, PRAC, iclusig, leukaemia, ponatinib
The EMA has recommended Ariad’s leukaemia drug Iclusig (ponatinib) should continue to be used under its current indication despite ongoing …
EMA in new Iclusig probe
December 9, 2013Sales and Marketing Ariad, EMA, iclusig, leukaemia
Europe’s medicines regulator has begun a new review of Ariad Pharmaceuticals’ leukaemia drug Iclusig, looking in particular at the risk …
Ariad cancer drug pulled amid safety fears
November 1, 2013Sales and Marketing Ariad, FDA, iclusig, leukaemia
Ariad Pharmaceuticals has been forced by the FDA to suspend sales of its blood cancer drug Iclusig given the high …
Ariad ditches CML trial
October 21, 2013Research and Development, Sales and Marketing Ariad, CML, iclusig
Ariad Pharmaceuticals has ditched its late-stage trial of Iclusig in patients with newly-diagnosed chronic myeloid leukemia (CML) after blood clots …
